Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Predicting outcomes for children with neuroblastoma.

Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandesompele J.

Discov Med. 2010 Jul;10(50):29-36. Review.

2.

Neuroblastoma: biology, prognosis, and treatment.

Park JR, Eggert A, Caron H.

Pediatr Clin North Am. 2008 Feb;55(1):97-120, x. doi: 10.1016/j.pcl.2007.10.014. Review.

PMID:
18242317
3.

Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.

Øra I, Eggert A.

Semin Cancer Biol. 2011 Oct;21(4):217-28. doi: 10.1016/j.semcancer.2011.07.002. Epub 2011 Jul 20. Review.

PMID:
21798350
4.

Risk estimation of neuroblastoma patients using molecular markers.

Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F.

Klin Padiatr. 2008 May-Jun;220(3):137-46. doi: 10.1055/s-2008-1065345. Review.

PMID:
18478485
5.

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.

De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F, Vandesompele J.

Clin Cancer Res. 2010 Mar 1;16(5):1532-41. doi: 10.1158/1078-0432.CCR-09-2607. Epub 2010 Feb 23.

6.

[Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].

Pérel Y, Valteau-Couanet D, Michon J, Lavrand F, Coze C, Bergeron C, Notz A, Plantaz D, Chastagner P, Bernard F, Thomas C, Rubie H.

Arch Pediatr. 2004 Jul;11(7):834-42. Review. French.

PMID:
15234382
7.

Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.

Spitz R, Betts DR, Simon T, Boensch M, Oestreich J, Niggli FK, Ernestus K, Berthold F, Hero B.

Cancer Genet Cytogenet. 2006 May;167(1):51-6.

PMID:
16682287
8.

[Management strategy in neuroblastoma].

Balwierz W.

Przegl Lek. 2004;61 Suppl 2:3-8. Review. Polish.

PMID:
15686038
9.

Current aspects of biology, risk assessment, and treatment of neuroblastoma.

Haase GM, Perez C, Atkinson JB.

Semin Surg Oncol. 1999 Mar;16(2):91-104. Review.

PMID:
9988866
10.

Neuroblastoma: Therapeutic strategies for a clinical enigma.

Modak S, Cheung NK.

Cancer Treat Rev. 2010 Jun;36(4):307-17. doi: 10.1016/j.ctrv.2010.02.006. Epub 2010 Mar 12. Review.

PMID:
20227189
11.

Neuroblastoma: biology, prognosis, and treatment.

Park JR, Eggert A, Caron H.

Hematol Oncol Clin North Am. 2010 Feb;24(1):65-86. doi: 10.1016/j.hoc.2009.11.011. Review.

PMID:
20113896
12.

[Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].

Ladenstein R, Ambros PF, Urban C, Ambros IM, Fink FM, Zoubek A, Grienberger H, Schmitt K, Kerbl R, Horcher E, Amann G, Höfler G, Heinzl H, Gadner H, Mutz I.

Klin Padiatr. 1996 Jul-Aug;208(4):210-20. German.

PMID:
8926686
13.

Neuroblastoma: a review of management and outcome.

Bhatnagar SN, Sarin YK.

Indian J Pediatr. 2012 Jun;79(6):787-92. doi: 10.1007/s12098-012-0748-2. Epub 2012 Apr 18. Review.

PMID:
22528697
14.

Comparative genomic hybridization reveals changes in DNA-copy number in poor-risk neuroblastoma.

Vettenranta K, Aalto Y, Wikström S, Knuutila S, Saarinen-Pihkala U.

Cancer Genet Cytogenet. 2001 Mar;125(2):125-30.

PMID:
11369055
15.

Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.

Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, Yu A, Brodeur GM, Hayes FA, Look AT.

J Natl Cancer Inst. 1997 Mar 5;89(5):373-80.

PMID:
9060959
16.

Risk-based management: current concepts of treating malignant solid tumors of childhood.

Grosfeld JL.

J Am Coll Surg. 1999 Oct;189(4):407-25. Review.

PMID:
10509467
17.

Prognostic impact of gene expression-based classification for neuroblastoma.

Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Weber A, Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P, Kaderali L, Simon T, Decarolis B, Theissen J, Westermann F, Brors B, Fischer M.

J Clin Oncol. 2010 Jul 20;28(21):3506-15. doi: 10.1200/JCO.2009.27.3367. Epub 2010 Jun 21.

PMID:
20567016
18.

The biologic basis for neuroblastoma heterogeneity and risk stratification.

Maris JM.

Curr Opin Pediatr. 2005 Feb;17(1):7-13. Review.

PMID:
15659956
19.

MYCN protein expression as a predictor of neuroblastoma prognosis.

Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V.

Clin Cancer Res. 1997 Oct;3(10):1699-706.

20.

Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B.

BMC Cancer. 2007 May 25;7:89. Review.

Supplemental Content

Support Center